AR065431A1 - Formas solidas que comprenden (-) -o-desmetilvenlafaxina y usos de las mismas. - Google Patents

Formas solidas que comprenden (-) -o-desmetilvenlafaxina y usos de las mismas.

Info

Publication number
AR065431A1
AR065431A1 ARP080100726A ARP080100726A AR065431A1 AR 065431 A1 AR065431 A1 AR 065431A1 AR P080100726 A ARP080100726 A AR P080100726A AR P080100726 A ARP080100726 A AR P080100726A AR 065431 A1 AR065431 A1 AR 065431A1
Authority
AR
Argentina
Prior art keywords
disorders
solid forms
demetilvenlafaxin
same
prevention
Prior art date
Application number
ARP080100726A
Other languages
English (en)
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of AR065431A1 publication Critical patent/AR065431A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formas solidas que comprenden un compuesto de utilidad en el tratamiento, prevencion y manejo de diversas condiciones y enfermedades. En particular, formas solidas que comprenden (-)-O-desmetilvenlafaxina, incluyendo sales de la misma, que tienenutilidad para el tratamiento, prevencion y manejo de condiciones y trastornos incluyendo, pero sin limitaciones, trastornos afectivos tales como depresion, trastornos bipolar y maniaco, trastorno de déficit atencional, trastorno de déficitatencional con hiperactividad, mal de Parkinson, epilepsia, trastornos de la funcion cerebral, obesidad y aumento de peso, incontinencia, demencia y trastornos relacionados.
ARP080100726A 2007-02-21 2008-02-21 Formas solidas que comprenden (-) -o-desmetilvenlafaxina y usos de las mismas. AR065431A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90295007P 2007-02-21 2007-02-21

Publications (1)

Publication Number Publication Date
AR065431A1 true AR065431A1 (es) 2009-06-10

Family

ID=39432564

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100726A AR065431A1 (es) 2007-02-21 2008-02-21 Formas solidas que comprenden (-) -o-desmetilvenlafaxina y usos de las mismas.

Country Status (18)

Country Link
US (2) US20090005457A1 (es)
EP (2) EP2500337A3 (es)
JP (1) JP5666140B2 (es)
KR (1) KR101528326B1 (es)
CN (1) CN101663263A (es)
AR (1) AR065431A1 (es)
AU (1) AU2008218997B2 (es)
BR (1) BRPI0807604A2 (es)
CA (1) CA2678599C (es)
ES (1) ES2609264T3 (es)
IL (1) IL200514A (es)
MX (1) MX2009008705A (es)
NZ (2) NZ599480A (es)
RU (1) RU2477269C2 (es)
SG (1) SG175611A1 (es)
TW (1) TWI446903B (es)
WO (1) WO2008103461A2 (es)
ZA (1) ZA200905698B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010523662A (ja) * 2007-04-09 2010-07-15 セプラコール・インコーポレイテッド 睡眠関連呼吸障害を処置するための方法及び組成物
CZ301503B6 (cs) * 2008-11-27 2010-03-24 Zentiva, A. S. Zpusob prípravy desvenlafaxinu a jeho solí
CZ302145B6 (cs) * 2009-07-15 2010-11-10 Zentiva, K. S. Zpusob prípravy desvenlafaxinu a jeho solí
CN102249936B (zh) * 2010-05-19 2014-09-17 江苏豪森医药集团有限公司 O-去甲基文拉法辛盐酸盐的水合物及其制备方法
US20120263838A1 (en) * 2011-04-12 2012-10-18 Geo. Pfau's Sons Company, Inc. Method for rendering animal materials
CN103772220A (zh) * 2013-12-03 2014-05-07 镇江圣安医药有限公司 1-[2-二甲基氨基-1-（4-甲氧基苯基）乙基]环己醇的新型衍生物及其应用
CN105348119B (zh) * 2015-11-04 2017-09-15 江苏豪森药业集团有限公司 晶状的文拉法辛代谢物及其制备方法
CN109771380A (zh) * 2017-11-10 2019-05-21 连云港恒运药业有限公司 去甲文拉法辛盐酸盐药物组合物及其制备方法
CN116199590A (zh) * 2022-12-26 2023-06-02 湖北美林药业有限公司 一种盐酸多巴酚丁胺及其注射剂

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4535186A (en) 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5213738A (en) 1990-05-15 1993-05-25 L. Perrigo Company Method for making a capsule-shaped tablet
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
AU5738700A (en) * 1999-06-15 2001-01-02 American Home Products Corporation Enantiomers of o-desmethyl venlafaxine
DK1360169T3 (da) * 2001-02-12 2007-11-26 Wyeth Corp Succinatsalt af O-desmethyl-venlafaxin
EP1451145A1 (en) * 2001-12-05 2004-09-01 Wyeth Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
MXPA04012347A (es) 2002-06-10 2005-02-25 Wyeth Corp Nueva sal formiato de o-desmetilvenlafaxina.
CN101257898A (zh) * 2005-07-06 2008-09-03 塞普拉科公司 艾司佐匹克隆与o-去甲基文拉法辛的组合以及治疗绝经期和心境障碍、焦虑症和认知障碍的方法

Also Published As

Publication number Publication date
US20090005457A1 (en) 2009-01-01
EP2500337A3 (en) 2012-12-26
RU2477269C2 (ru) 2013-03-10
WO2008103461A3 (en) 2008-11-13
TW200901955A (en) 2009-01-16
EP2114863B1 (en) 2016-10-05
KR20090113904A (ko) 2009-11-02
MX2009008705A (es) 2009-09-10
AU2008218997B2 (en) 2013-06-20
CN101663263A (zh) 2010-03-03
TWI446903B (zh) 2014-08-01
KR101528326B1 (ko) 2015-06-11
BRPI0807604A2 (pt) 2014-07-22
EP2114863A2 (en) 2009-11-11
IL200514A (en) 2013-12-31
AU2008218997A1 (en) 2008-08-28
EP2500337A2 (en) 2012-09-19
IL200514A0 (en) 2010-04-29
CA2678599A1 (en) 2008-08-28
JP2010519300A (ja) 2010-06-03
JP5666140B2 (ja) 2015-02-12
ZA200905698B (en) 2010-10-27
NZ579137A (en) 2012-05-25
WO2008103461A2 (en) 2008-08-28
ES2609264T3 (es) 2017-04-19
NZ599480A (en) 2013-10-25
US20160355457A1 (en) 2016-12-08
CA2678599C (en) 2015-11-10
SG175611A1 (en) 2011-11-28
RU2009135016A (ru) 2011-03-27

Similar Documents

Publication Publication Date Title
AR065431A1 (es) Formas solidas que comprenden (-) -o-desmetilvenlafaxina y usos de las mismas.
CY1120369T1 (el) Θεραπεια νευρολογικων διαταραχων βασει βακλοφαινης και ακαμπροσατης
CL2008003316A1 (es) Forma cristalina vi de la agomelatina; procedimientos de preparacion; composicion farmaceutica, util para el tratamiento de estres, ansiedad, depresion mayor, ataques de panico, enfermedad de parkinson, epilepsia, enfermedad de alzheimer.
BR112015010663A2 (pt) formas de dosagem de ruxolitinib de liberação sustentada
CL2012001673A1 (es) Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras.
NI200600306A (es) Derivados de sulfamida y sulfamato para el tratamiento de la epilepsia y trastornos relacionados
ECSP077275A (es) Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos
CL2013001073A1 (es) Compuestos derivados de 6-amino-nicotinamidas sustituidas, como moduladores de kcnq2/3; composicion farmaceutica que los comprende, util para el tratamiento y/o profilaxis de trastornos y/o enfermedades seleccionadas de dolor, epilepsia, ansiedad, enfermedades cognitivas, entre otras.
GT201000015A (es) Sulfonamidas como moduladores de trpms
CL2011000137A1 (es) Uso de compuestos derivados de 4,5-dihidro-oxazol-2-ilamina para tratar trastornos de ansiedad, trastornos bipolar, esquizofrenia, enfermedades neurológicas, epilepsias, migraña, trastornos metabólicos, trastornos cardiovasculares, entre otros; compuestos derivados de 4,5-dihidroxazol-2-ilamino; proceso de síntesis
UY33277A (es) Compuestos de anillo espiro-tetraciclico como moduladores de beta-secretasa y métodos de uso
DOP2006000205A (es) Derivados de fenil-1,2,4-oxadiazolona con grupo fenilo, procedimientos para su preparacion y su uso como productos farmaceuticos.
DOP2014000230A (es) Agentes para tratar trastornos que implican la modulación de receptores de rianodina
DOP2013000130A (es) Compuestos de pirimidinona para uso en el tratamiento de las enfermedades o condiciones mediada por lp - pla2
CL2012001031A1 (es) Compuestos derivados de 2-oxo-1-pirrolidinil-imidazotiadiazol; composición farmacéutica que los comprende; útiles para el tratamiento de la epilepsia, transtornos neurológicos, entre otros.
CY1118966T1 (el) Νεες συνθεσεις για την προληψη και/ή την θεραπεια εκφυλιστικων διαταραχων του κεντρικου νευρικου συστηματος
CO6382089A2 (es) Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias
CL2012002175A1 (es) Composicion farmaceutica oral de liberacion prolongada que comprende un agente activo de fracciones de propargilamina y aminoindano; metodo de preparacion; uso en el tratamiento de enfermedades neurodegenerativas o lesiones en el sistema nervioso tales como parkinson o alzheimer, un accidente cerebrovascular o lesion traumatica cerebral.
UY29777A1 (es) Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos del sueno en pacientes con depresión.
CO6331428A2 (es) Compuestos que comprenden un grupo ciclobutoxi
CY1118297T1 (el) Θεραπευτικες χρησεις της εσλικαρβαζεπινης
BR112015004942A2 (pt) benzimidazóis como agentes ativos do snc
CO6481008A2 (es) Canfenos arilados novedosos, procesos para su preparación y usos
AR112472A1 (es) Forma de sales cristalinas de amida de levodopa y métodos para elaborarlas y usarlas
BR112012022255A2 (pt) composição farmaceuticaestabilizada

Legal Events

Date Code Title Description
FC Refusal